hero image
Annie Wong-Beringer, PharmD, FCCP, FIDSA - USC School of Pharmacy. Los Angeles, CA, US

Annie Wong-Beringer, PharmD, FCCP, FIDSA Annie Wong-Beringer, PharmD, FCCP, FIDSA

Associate Dean for Research Affairs & Professor of Clinical Pharmacy | USC School of Pharmacy


An expert in bacterial resistance and virulence, host microbial interactions and host immune response.






loading image loading image



Social Media


Dr. Wong-Beringer joined the faculty at the University of Southern California School of Pharmacy in July 2003 as an Associate Professor of Clinical Pharmacy. She is a graduate of USC School of Pharmacy. She received her postdoctoral residency in pharmacy practice and fellowship training in infectious diseases pharmacotherapy at the University of California, San Francisco. Her clinical practice and research is at Huntington Hospital, Pasadena.

Dr. Wong-Beringer has been a principal investigator on a number of research studies on antimicrobial resistance and bacterial virulence and their impact on patient outcomes. Her research focuses on Pseudomonas aeruginosa and Staphylococcus aureus. Her recent work has expanded to include investigations on the contribution of host immune response and immunogenetics to outcomes of infection. Dr. Wong-Beringer has authored numerous journal articles and book chapters in the area of her clinical expertise and research.

Areas of Expertise (11)


Host microbial interactions

Host immune response

Pseudomonas aeruginosa

Antimicrobial Resistance

Pharmacotherapy of Infectious Diseases

Antifungal Therapy

Staphylococcus aureus


Bacterial resistance


Education (2)

USC School of Pharmacy: Pharm.D.

UCSF School of Pharmacy: Residency & Fellowship, Infectious Diseases

Affiliations (1)

  • Fellow, Infectious Diseases Society of America (FIDSA)

Selected Media Appearances (1)

Each day of S. aureus bacteremia increases mortality risk by 16%



Every day a blood culture returns positive for Staphylococcus aureus bacteremia, a patient’s risk for mortality increases, with a significant increase for risk beginning at day 3, according to findings from a multicenter, prospective, observational study.

view more

Research Focus (1)

Anti-Infective Pharmacology Research

Clinicians are faced with an ever-increasing tide of antimicrobial resistance coupled with the dwindling antibiotic development of novel agents to treat infections caused by multi-drug resistant bacteria, specifically, MRSA and Pseudomonas aeruginosa. Our laboratory combines a molecular and pharmacological approach to address this therapeutic challenge. Our group focuses on gaining a deeper understanding of host-microbial interactions during acute and chronic infections with the goal of identifying potential therapeutic target against bacterial virulence or modulation of host response. We will exploit existing therapies with known safety profiles as well as novel therapies in drug development. Our research program encompasses in vitro cellular models of infection, epidemiologic and outcomes studies, and prospective clinical trials.

Selected Articles (5)

Antimicrobial Stewardship Opportunities in Patients with Bacteremia Not Identified by BioFire FilmArray

Journal of Clinical Microbiology

P. Ny, A. Ozaki, J. Pallares, P. Nieberg, A. Wong-Beringer

2019 A subset of bacteremia cases are caused by organisms not detected by a rapid-diagnostics platform, BioFire blood culture identification (BCID), with unknown clinical characteristics and outcomes. Patients with ≥1 positive blood culture over a 15-month period were grouped by negative (NB-PC) versus positive (PB-PC) BioFire BCID results and compared with respect to demographics, infection characteristics, antibiotic therapy, and outcomes (length of hospital stay [LOS] and in-hospital mortality). Six percent of 1,044 positive blood cultures were NB-PC. The overall mean age was 65 ± 22 years, 54% of the patients were male, and most were admitted from home; fewer NB-PC had diabetes (19% versus 31%, P = 0.0469), although the intensive care unit admission data were similar. Anaerobes were identified in 57% of the bacteremia cases from the NB-PC group by conventional methods: Bacteroides spp. (30%), Clostridium (11%), and Fusobacterium spp. (8%). Final identification of the NB-PC pathogen was delayed by 2 days (P < 0.01) versus the PB-PC group. The sources of bacteremia were more frequently unknown for the NB-PC group (32% versus 11%, P < 0.01) and of pelvic origin (5% versus 0.1%, P < 0.01) compared to urine (31% versus 9%, P < 0.01) for the PB-PC patients. Fewer NB-PC patients received effective treatment before (68% versus 84%, P = 0.017) and after BCID results (82% versus 96%, P = 0.0048). The median LOS was similar (7 days), but more NB-PC patients died from infection (26% versus 8%, P < 0.01). Our findings affirm the need for the inclusion of anaerobes in BioFire BCID or other rapid diagnostic platforms to facilitate the prompt initiation of effective therapy for bacteremia.

view more

Utility of qSOFA score in identifying patients at risk for poor outcome in Staphylococcus aureus bacteremia

BMC Infectious Diseasesvolume

Emi Minejima, Vanessa Delayo, Mimi Lou, Pamela Ny, Paul Nieberg, Rosemary C. She & Annie Wong-Beringer

2019 The prognostic capability of the quick Sequential Organ Failure Assessment (qSOFA) bedside scoring tool is uncertain in non-ICU patients with sepsis due to bacteremia given the low number of patients previously evaluated.

view more

Leveraging Antimicrobial Stewardship in the Emergency Department to Improve the Quality of Urinary Tract Infection Management and Outcomes

Open Forum Infectious Diseases

Sarah C J Jorgensen, Samantha L Yeung, Mira Zurayk, Jill Terry, Maureen Dunn, Paul Nieberg, Jean Pallares, Annie Wong-Beringer

2018 The complex and fast-paced emergency department (ED) practice setting presents unique challenges that demand a tailored approach to antimicrobial stewardship. In this article, we describe the strategies applied by 1 institution’s antimicrobial stewardship program (ASP) that were successful in improving prescribing practices and outcomes for urinary tract infection (UTI) in the ED.

view more

Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates

Journal of Clinical Microbiology

Romney M. Humphries, Janet A. Hindler, Paul Magnano, Annie Wong-Beringer, Robert Tibbetts, Shelley A. Miller

2018 The performance characteristics of the ceftolozane-tazobactam (C-T) Etest (bioMérieux, Marcy l'Etoile, France), MIC test strips (MTS; Liofilchem, Italy), and disk diffusion (Hardy, Santa Ana, CA) were evaluated for a collection of 308 beta-lactam-resistant isolates of Pseudomonas aeruginosa recovered from three institutions in Los Angeles, CA. Reference testing was performed by the reference broth microdilution (rBMD) method. MIC and disk results were interpreted using Clinical and Laboratory Standards Institute breakpoints. Overall, 72.5% of the isolates were susceptible to C-T by rBMD. Etest and disk diffusion demonstrated acceptable performance, whereas MTS yielded a greater than acceptable percentage of minor errors. Categorical agreement was 96.8% for Etest, 87.0% for MTS, and 92.9% for disk diffusion. No very major errors were observed by any test, and no major errors (ME) were observed by Etest or disk diffusion. Two ME (0.9% of susceptible isolates) were observed by MTS. The incidence of minor errors was 3.2%, 12.3%, and 7.1% for Etest, MTS, and disk diffusion, respectively. Essential agreement (EA) for Etest was excellent, at 97.7%, whereas the MICs obtained by MTS tended to be 1 to 2 dilutions higher than those obtained by rBMD, with an EA of 87.0%.

view more

Risk factors for early return visits to the emergency department in patients with urinary tract infection

The American Journal of Emergency Medicine

Sarah Jorgensen, Mira Zurayk, Samantha Yeung, Jill Terry, Maureen Dunn, Paul Nieberg, Annie Wong-Beringer

2018 Optimal management of urinary tract infections (UTIs) in the emergency department (ED) is challenging due to high patient turnover, decreased continuity of care, and treatment decisions made in the absence of microbiologic data. We sought to identify risk factors for return visits in ED patients treated for UTI.

view more